MSF offices closed for Thanksgiving
Immune programming cells may hold key to new treatments
Study: Myelin mouse model may not apply to humans
Nov. 18 Teleconference Not Available On-Demand
Lemtrada Receives FDA Approval for MS
Study: Key protein reduces MS severity in mice
MS Coalition releases new consensus paper, summary
First patient enrolls in Phase II trial to evaluate vatelizumab
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
Website Design by SimplexWeb
© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved